REG - C4X Discovery - Board Update

C4X Discovery HoldingsAnnouncement

18/01/2024 07:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20240118:nRSR0552Aa&default-theme=true

RNS Number : 0552A  C4X Discovery Holdings PLC  18 January 2024

 

 

 

C4X Discovery Holdings plc

("C4XD", "C4X Discovery" or the "Company")

 

Board Change

 

18 January 2024 - C4X Discovery Holdings plc (AIM: C4XD), a pioneering Drug
Discovery company, today announces that Mario Polywka, Non-Executive Director,
has stepped down from the Board of Directors with immediate effect in order to
focus on his recent appointment as Interim Chief Executive Officer of Evotec
SE.

 

The Company intends to appoint a replacement Non-Executive Director and a
further announcement will be made in due course.

 

Clive Dix, Interim Executive Chairman and Chief Executive Officer of C4X
Discovery, said: "It has been a pleasure working with Mario since he joined
the Board in 2021 and during this time C4X Discovery has benefitted from his
deep industry insights and experience. We wish him all the best in his new
role."

 

 

- Ends -

 

 

Contacts

 

 C4X Discovery Holdings
 Mo Noonan, Communications                       +44 (0)787 6444977

 Panmure Gordon (UK) Limited (NOMAD and Broker)
 Freddy Crossley, Emma Earl (Corporate Finance)  +44 (0)20 7886 2500
 Rupert Dearden (Corporate Broking)

 C4X Discovery Media - ICR Consilium
 Mary-Jane Elliott, Chris Gardner, Matthew Neal  +44 (0)203 709 5700
 C4X Discovery Holdings

 

 

 

 

 

 

 

Notes to Editors:

 

About C4X Discovery

C4X Discovery (C4XD) is a pioneering Drug Discovery company, combining
scientific expertise with cutting-edge technologies to efficiently deliver
world‑leading medicines. We have a highly valuable and differentiated
approach to Drug Discovery through our enhanced molecular design and patient
stratification capabilities, generating small molecule drug candidates across
multiple disease indications focused on immuno-inflammation. We are advancing
our internal portfolio which ranges from early-stage target opportunities to
late-stage Drug Discovery programmes and we have two commercially partnered
programmes with Sanofi and AstraZeneca, and one clinical stage candidate which
has been acquired by Indivior.

 

For more information visit us at www.c4xdiscovery.com
(http://www.c4xdiscovery.com) or follow us on twitter @C4XDiscovery.

 

 

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  BOAQDLFFZFLZBBL